Q2 2025 · 13F-HR
5AM Venture Management, LLCholdings as filed
Filed 2025-08-14 · accession 0001085146-25-005241
$260.1M
Reported value
29
Positions
2025-06-30
Period end
The Brief · 5AM Venture Management, LLC · Q2 2025
AI · grounded in 13F
5AM Venture Management, LLC established a new position in SKYE valued at $41.4M. The fund also initiated new stakes in TRDA for $28.9M and DNTH for $18.3M. Additional new positions include ELVN, PHVS, and MLTX. The fund ended the period with 29 positions and total AUM of $260.1M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 83086J200 | SKYE | SKYE BIOSCIENCE INC | $41.4M | 15.9% | 9,913,168 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $29.0M | 11.1% | 4,308,379 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $18.3M | 7.05% | 984,725 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $15.5M | 5.96% | 772,477 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $14.0M | 5.40% | 797,600 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $13.3M | 5.12% | 282,313 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $10.9M | 4.20% | 830,945 | Common | SOLE |
| 929033108 | VOR | VOR BIOPHARMA INC | $10.3M | 3.96% | 6,361,723 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $10.3M | 3.96% | 736,595 | Common | SOLE |
| 878972108 | TECX | TECTONIC THERAPEUTIC INC | $10.2M | 3.91% | 511,660 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $10.1M | 3.89% | 497,270 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $9.9M | 3.80% | 1,050,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $9.0M | 3.46% | 939,298 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $7.1M | 2.75% | 170,000 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $7.0M | 2.68% | 572,665 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $6.9M | 2.64% | 5,405,404 | Common | SOLE |
| G1110E107 | BHVN | BIOHAVEN LTD | $6.8M | 2.60% | 478,972 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $5.0M | 1.93% | 189,593 | Common | SOLE |
| 810648105 | SCPH | SCPHARMACEUTICALS INC | $4.6M | 1.76% | 1,200,647 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $4.2M | 1.63% | 2,927,915 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $3.6M | 1.37% | 2,353,304 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $2.8M | 1.07% | 310,000 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $2.8M | 1.06% | 476,200 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $2.4M | 0.93% | 800,000 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $1.4M | 0.54% | 995,841 | Common | SOLE |
| 75120L100 | RLYB | RALLYBIO CORP | $1.2M | 0.47% | 3,630,724 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $1.2M | 0.45% | 541,666 | Common | SOLE |
| 98943L107 | ZNTL | ZENTALIS PHARMACEUTICALS INC | $568,400 | 0.22% | 490,000 | Common | SOLE |
| 59045L106 | MRSN | MERSANA THERAPEUTICS INC | $386,280 | 0.15% | 1,305,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.